![Yuri Maricich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yuri Maricich
Hoofd Techniek/Wetenschap/O&O bij
PEAR THERAPEUTICS, INC.
Vermogen: 26 603 $ op 31-05-2026
Profiel
Yuri Maricich currently works at CAMP4 Therapeutics Corp., as Chief Medical Officer from 2023, Pear Therapeutics, Inc., as Chief Medical Officer & Head-Development, and Angelini Ventures SpA, as Advisor.
Dr. Maricich also formerly worked at Cavion LLC, as Chief Scientific Officer & Senior Medical Director from 2014 to 2016, Xdynia LLC, as President from 2011 to 2014, and Pear Therapeutics (US), Inc., as Chief Medical Officer & Head-Development from 2017 to 2023.
Dr. Maricich received his undergraduate degree from the University of Notre Dame, doctorate degree from the University of Washington, and Masters Business Admin degree from Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-04-2026 | 6.060 ( 0,01% ) | 26 603 $ | 31-05-2026 |
Actieve functies van Yuri Maricich
| Bedrijven | Functie | Begin |
|---|---|---|
| PEAR THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
| CAMP4 THERAPEUTICS CORPORATION | Hoofd Techniek/Wetenschap/O&O | 01-08-2023 |
Angelini Ventures SpA
 Angelini Ventures SpA Investment ManagersFinance Angelini Ventures invests in companies located in North America, Europe, Israel and Italy. The firm focuses on digital healthcare, connected medical devices and life sciences. It participates in early stage capital requirements. | Consultant / Adviseur | - |
Eerdere bekende functies van Yuri Maricich
| Bedrijven | Functie | Einde |
|---|---|---|
Pear Therapeutics (US), Inc.
 Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications | Hoofd Techniek/Wetenschap/O&O | 01-01-2023 |
Cavion LLC | Hoofd Techniek/Wetenschap/O&O | 01-01-2016 |
Xdynia LLC
 Xdynia LLC Pharmaceuticals: MajorHealth Technology Provides preclinical pharmaceutical services | President | 01-01-2014 |
Opleiding van Yuri Maricich
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
9
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xdynia LLC
Xdynia LLC Pharmaceuticals: MajorHealth Technology Provides preclinical pharmaceutical services | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications | Technology Services |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Cavion LLC | |
Pear Therapeutics, Inc.
 Pear Therapeutics, Inc. Packaged SoftwareTechnology Services Operates as a commercial stage healthcare company that develops software based medicines | Technology Services |
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures invests in companies located in North America, Europe, Israel and Italy. The firm focuses on digital healthcare, connected medical devices and life sciences. It participates in early stage capital requirements. | Finance |
